Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference
Akebia Therapeutics (Nasdaq: AKBA) announced its participation in the virtual H.C. Wainwright Bioconnect 2021 Conference from January 11-14, 2021. CEO John P. Butler will partake in a fireside chat during the event. Investors can access the recorded presentation starting January 11 on the company's website. Akebia is focused on developing therapeutics for kidney disease, striving to improve the lives of affected individuals. Founded in 2007 and headquartered in Cambridge, Massachusetts, Akebia emphasizes its commitment to kidney health.
- None.
- None.
CAMBRIDGE, Mass., Jan. 6, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect 2021 Conference, which takes place virtually January 11 – 14, 2021.
The recorded presentation will be available on the Investors section of the Company's website at https://ir.akebia.com beginning Monday, January 11.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Kristen K. Sheppard, Esq.
ir@akebia.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-hc-wainwright-bioconnect-2021-conference-301201492.html
SOURCE Akebia Therapeutics
FAQ
When is Akebia Therapeutics presenting at the H.C. Wainwright Bioconnect 2021 Conference?
Who from Akebia Therapeutics will speak at the conference?
Where can I find the recorded presentation from Akebia Therapeutics?
What is the purpose of Akebia Therapeutics?